MovDisordV3, PascalFrancis, Corpus, bibRecord, 000B66

Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times

Identifieur interne : 000B66 ( PascalFrancis/Corpus ); précédent : 000B65; suivant : 000B67

Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times

Auteurs : YING JIAO ZHAO ; HWEE LIN WEE ; Yiong-Huak Chan ; SOO HOON SEAH ; WING LOK AU ; PUAY NGOH LAU ; Emmanuel Camara Pica ; SHU CHUEN LI ; NAN LUO ; Louis C. S. Tan

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0233091

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Transition.

English descriptors

KwdEn :
- Nervous system diseases, Parkinson disease, Transition.

Abstract

This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times`
A11	`01`	`1`		`@1 YING JIAO ZHAO`
A11	`02`	`1`		`@1 HWEE LIN WEE`
A11	`03`	`1`		`@1 CHAN (Yiong-Huak)`
A11	`04`	`1`		`@1 SOO HOON SEAH`
A11	`05`	`1`		`@1 WING LOK AU`
A11	`06`	`1`		`@1 PUAY NGOH LAU`
A11	`07`	`1`		`@1 CAMARA PICA (Emmanuel)`
A11	`08`	`1`		`@1 SHU CHUEN LI`
A11	`09`	`1`		`@1 NAN LUO`
A11	`10`	`1`		`@1 TAN (Louis C. S.)`
A14	`01`			`@1 Department of Pharmacy, National University of Singapore @3 SGP @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore @3 SGP @Z 3 aut.`
A14	`03`			`@1 Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute @3 SGP @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 7 aut. @Z 10 aut.`
A14	`04`			`@1 Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle @3 AUS @Z 8 aut.`
A14	`05`			`@1 Department of Epidemiology and Public Health, National University of Singapore @3 SGP @Z 9 aut.`
A14	`06`			`@1 Centre for Health Services Research, National University of Singapore @3 SGP @Z 9 aut.`
A20				`@1 710-716`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000181078480070`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 28 ref.`
A47	`01`	`1`		`@0 10-0233091`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Transition @5 09`
C03	`03`	`X`	`ENG`	`@0 Transition @5 09`
C03	`03`	`X`	`SPA`	`@0 Transición @5 09`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 158`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 10-0233091 INIST
ET :	Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times
AU :	YING JIAO ZHAO; HWEE LIN WEE; CHAN (Yiong-Huak); SOO HOON SEAH; WING LOK AU; PUAY NGOH LAU; CAMARA PICA (Emmanuel); SHU CHUEN LI; NAN LUO; TAN (Louis C. S.)
AF :	Department of Pharmacy, National University of Singapore/Singapour (1 aut., 2 aut.); Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore/Singapour (3 aut.); Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute/Singapour (4 aut., 5 aut., 6 aut., 7 aut., 10 aut.); Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle/Australie (8 aut.); Department of Epidemiology and Public Health, National University of Singapore/Singapour (9 aut.); Centre for Health Services Research, National University of Singapore/Singapour (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 6; Pp. 710-716; Bibl. 28 ref.
LA :	Anglais
EA :	This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.
CC :	002B17; 002B17G
FD :	Maladie de Parkinson; Pathologie du système nerveux; Transition
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central
ED :	Parkinson disease; Nervous system diseases; Transition
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Parkinson enfermedad; Sistema nervioso patología; Transición
LO :	INIST-20953.354000181078480070
ID :	10-0233091

Links to Exploration step

Pascal:10-0233091

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times</title>
<author><name sortKey="Ying Jiao Zhao" sort="Ying Jiao Zhao" uniqKey="Ying Jiao Zhao" last="Ying Jiao Zhao">YING JIAO ZHAO</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hwee Lin Wee" sort="Hwee Lin Wee" uniqKey="Hwee Lin Wee" last="Hwee Lin Wee">HWEE LIN WEE</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name>
<affiliation><inist:fA14 i1="02"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Soo Hoon Seah" sort="Soo Hoon Seah" uniqKey="Soo Hoon Seah" last="Soo Hoon Seah">SOO HOON SEAH</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wing Lok Au" sort="Wing Lok Au" uniqKey="Wing Lok Au" last="Wing Lok Au">WING LOK AU</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Puay Ngoh Lau" sort="Puay Ngoh Lau" uniqKey="Puay Ngoh Lau" last="Puay Ngoh Lau">PUAY NGOH LAU</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camara Pica, Emmanuel" sort="Camara Pica, Emmanuel" uniqKey="Camara Pica E" first="Emmanuel" last="Camara Pica">Emmanuel Camara Pica</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shu Chuen Li" sort="Shu Chuen Li" uniqKey="Shu Chuen Li" last="Shu Chuen Li">SHU CHUEN LI</name>
<affiliation><inist:fA14 i1="04"><s1>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nan Luo" sort="Nan Luo" uniqKey="Nan Luo" last="Nan Luo">NAN LUO</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Epidemiology and Public Health, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Centre for Health Services Research, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0233091</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0233091 INIST</idno>
<idno type="RBID">Pascal:10-0233091</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B66</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times</title>
<author><name sortKey="Ying Jiao Zhao" sort="Ying Jiao Zhao" uniqKey="Ying Jiao Zhao" last="Ying Jiao Zhao">YING JIAO ZHAO</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hwee Lin Wee" sort="Hwee Lin Wee" uniqKey="Hwee Lin Wee" last="Hwee Lin Wee">HWEE LIN WEE</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Chan, Yiong Huak" sort="Chan, Yiong Huak" uniqKey="Chan Y" first="Yiong-Huak" last="Chan">Yiong-Huak Chan</name>
<affiliation><inist:fA14 i1="02"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Soo Hoon Seah" sort="Soo Hoon Seah" uniqKey="Soo Hoon Seah" last="Soo Hoon Seah">SOO HOON SEAH</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wing Lok Au" sort="Wing Lok Au" uniqKey="Wing Lok Au" last="Wing Lok Au">WING LOK AU</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Puay Ngoh Lau" sort="Puay Ngoh Lau" uniqKey="Puay Ngoh Lau" last="Puay Ngoh Lau">PUAY NGOH LAU</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Camara Pica, Emmanuel" sort="Camara Pica, Emmanuel" uniqKey="Camara Pica E" first="Emmanuel" last="Camara Pica">Emmanuel Camara Pica</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shu Chuen Li" sort="Shu Chuen Li" uniqKey="Shu Chuen Li" last="Shu Chuen Li">SHU CHUEN LI</name>
<affiliation><inist:fA14 i1="04"><s1>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nan Luo" sort="Nan Luo" uniqKey="Nan Luo" last="Nan Luo">NAN LUO</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Epidemiology and Public Health, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>Centre for Health Services Research, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tan, Louis C S" sort="Tan, Louis C S" uniqKey="Tan L" first="Louis C. S." last="Tan">Louis C. S. Tan</name>
<affiliation><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Transition</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Transition</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>YING JIAO ZHAO</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>HWEE LIN WEE</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHAN (Yiong-Huak)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SOO HOON SEAH</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WING LOK AU</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PUAY NGOH LAU</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CAMARA PICA (Emmanuel)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SHU CHUEN LI</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>NAN LUO</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>TAN (Louis C. S.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Pharmacy, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute</s1>
<s3>SGP</s3>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle</s1>
<s3>AUS</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Epidemiology and Public Health, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Centre for Health Services Research, National University of Singapore</s1>
<s3>SGP</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>710-716</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000181078480070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>28 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0233091</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Transition</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Transition</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Transición</s0>
<s5>09</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>158</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 10-0233091 INIST</NO>
<ET>Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times</ET>
<AU>YING JIAO ZHAO; HWEE LIN WEE; CHAN (Yiong-Huak); SOO HOON SEAH; WING LOK AU; PUAY NGOH LAU; CAMARA PICA (Emmanuel); SHU CHUEN LI; NAN LUO; TAN (Louis C. S.)</AU>
<AF>Department of Pharmacy, National University of Singapore/Singapour (1 aut., 2 aut.); Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore/Singapour (3 aut.); Parkinson's Disease and Movement Disorders Center, Department of Neurology, National Neuroscience Institute/Singapour (4 aut., 5 aut., 6 aut., 7 aut., 10 aut.); Discipline of Pharmacy & Experimental Pharmacology, School of Biomedical Sciences, University of Newcastle/Australie (8 aut.); Department of Epidemiology and Public Health, National University of Singapore/Singapour (9 aut.); Centre for Health Services Research, National University of Singapore/Singapour (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2010; Vol. 25; No. 6; Pp. 710-716; Bibl. 28 ref.</SO>
<LA>Anglais</LA>
<EA>This study was carried out to evaluate progression in Parkinson's disease (PD) by analyzing time taken to transit from one Hoehn and Yahr (H&Y) stage to the next stage and to investigate the variables that would be associated with H&Y transition times using a large PD database that contained prospectively collected information. Data were obtained from the movement disorder database of the National Neuroscience Institute in Singapore. Kaplan-Meier (KM) survival analysis was adopted to investigate the time taken to progress through various H&Y stages. Cox regression analysis was used to examine the association between the baseline variables at the entry point of each H&Y stage and the progression to the next stage. A total of 695 patients (mean age: 65.2, male: 57.3%) were studied. Using KM analysis, the median time taken to transit from H&Y stage 1 to 2, 2 to 2.5, 2.5 to 3 were 20, 62, and 25 months, respectively ; whereas the median time taken to progress from stage 3 to 4 and 4 to 5 were 24 and 26 months, respectively. Cox regression analysis revealed that older age-at-diagnosis, longer PD duration, and higher Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at baseline were associated with a significantly faster progression through various H&Y stages. Gender and ethnicity were not associated with disease progression. In conclusion, H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.</EA>
<CC>002B17; 002B17G</CC>
<FD>Maladie de Parkinson; Pathologie du   système nerveux; Transition</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Parkinson disease; Nervous system diseases; Transition</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Parkinson enfermedad; Sistema nervioso patología; Transición</SD>
<LO>INIST-20953.354000181078480070</LO>
<ID>10-0233091</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B66 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000B66 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:10-0233091
   |texte=   Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times

Progression of Parkinson's Disease as Evaluated by Hoehn and Yahr Stage Transition Times

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri